Supplementary information, Fig. S3. In this figure, cancer cells were treated with DM- α KG (15 mM) for 24 hours to assess DR6 oxidation and pyroptotic features (including morphology, GSDMC cleavage, and LDH release), unless specially indicated otherwise.

- (a) Inhibitors, Genistein or MβCD, showed no effect on DM-αKG-induced DR6 oxidation. HeLa cells were pretreated with Genistein and MβCD for 2 hours.
- (**b**) The knockdown efficiency of CLTA, CLTB, CLAC, DNM1 and DNM2 in HeLa cells as determined by RT-qPCR.
- (**c**, **d**, **e**) Effect of CLTs on DM-αKG-induced caspase-8 activation (d), pyroptotic morphology (d), GSDMC cleavage and LDH release (e). CLTA, CLTB, and CLAC had first been knocked down in HeLa cells.
- (**f**, **g**, **h**) Effect of DNMs on DM-αKG-induced pyroptotic morphology (f), caspase-8 activation (g), GSDMC cleavage and LDH release (h). DNM1 and DNM2 had first been knocked down in the cells.
- (i) Genistein or MβCD impaired DM-αKG-induced GSDMC cleavage in SGC-7901(top) and B16 (bottom) cells.

Tubulin was used to determine the amount of loading proteins. All data are presented as the mean \pm SEM of two or three independent experiments. *** p<0.001. The data

were analyzed using two-way ANOVA followed by the Bonferroni test.

Supplementary information, Figure S3









